GelMEDIX is a biotechnology company developing regenerative therapies to restore vision, focusing on cell-based treatments and biomaterials for retinal diseases. The company is advancing GMX-101, an RPE cell therapy for late-stage Geographic Atrophy, and a proprietary injectable hydrogel scaffold platform engineered to optimize delivery, efficacy, and safety of cell and gene therapies.
Leadership & Board
Current Number of Employees9
Current LinkedIn Followers1,144
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$13M
Total Amount Raised$13M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$13M
Latest Funding Amount$13M
Latest Funding RoundSeed Round
Latest Funding RoundSeed Round
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
GelMEDIX had 9 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
9Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
GelMEDIX had 1,144 followers as of September 28, 2026. The number of followers increased by 0 (0.00%) week-over-week.
1,144Latest Followers Count
0(0.00%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.